Of importance in the context of some of the critical signalling pathways in MM, preclinical data have shown that selinexor in MM models reactivates multiple TSPs relevant to MM, inhibits NF‐kB signalling, reduces c‐Myc levels, and reactivates GR signalling in combination with dexamethasone [24–26, 29, 33]. Here, NFKB1 is linked to Miyoshi myopathy.